OmniSeq, Labcorp launch new oncology test

By staff writers

June 14, 2021 -- OmniSeq and Labcorp have launched OmniSeq Insight, a new test based on next-generation sequencing that's intended to help improve oncology treatment and outcomes.

OmniSeq Insight is a solid tumor test that combines genomic and immune profiling with immune gene expression data, according to the firm. Users receive test results in a report that includes a summary of U.S. Food and Drug Administration-approved therapies that match the tumor profile; they also receive recommendations for treatment based on information from a proprietary database that includes National Comprehensive Cancer Network (NCCN) guidelines.

OmniSeq is offering the test in the U.S. through Labcorp and in Canada through Dynacare, a Labcorp subsidiary, it said.

Labcorp to buy intellectual property from Myriad Genetics
Labcorp plans to buy some of Myriad Genetics' operating assets and intellectual property from its autoimmune business unit, including its Vectra rheumatoid...
Labcorp adds new COVID-19 antigen test to repertoire
Labcorp has added a new high sensitivity antigen test for screening for active COVID-19 disease to its testing offerings. The nasal swab test was developed...
CDC awards Labcorp SARS-CoV-2 sequencing contract
The U.S. Centers for Disease Control and Prevention (CDC) has awarded Labcorp a contract to provide genomic sequencing of samples of the SARS-CoV-2 virus.
Labcorp gets EUA for Pixel at-home COVID-19 kits
Labcorp has received an emergency use authorization (EUA) from the U.S. Food and Drug Administration for Pixel by Labcorp, a kit that will enable users...
Labcorp revenue, earnings surge in Q3
Revenue gains from COVID-19 testing helped propel Labcorp to a 33% increase in revenue in its third quarter. The company said that revenue climbed due...

Copyright © 2021

Last Updated np 9/1/2021 12:29:24 PM